Cargando…
The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential
Leukocyte cell-derived chemotaxin-2 (LECT2, also named ChM-II), initially identified as a chemokine mediating neutrophil migration, is a multifunctional secreted factor involved in diverse physiological and pathological processes. The high sequence similarity of LECT2 among different vertebrates mak...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034042/ https://www.ncbi.nlm.nih.gov/pubmed/36969200 http://dx.doi.org/10.3389/fimmu.2023.1158083 |
_version_ | 1784911122158059520 |
---|---|
author | Zhu, Ming-Hui Liu, Yan-Jun Li, Chang-Yun Tao, Fan Yang, Guan-Jun Chen, Jiong |
author_facet | Zhu, Ming-Hui Liu, Yan-Jun Li, Chang-Yun Tao, Fan Yang, Guan-Jun Chen, Jiong |
author_sort | Zhu, Ming-Hui |
collection | PubMed |
description | Leukocyte cell-derived chemotaxin-2 (LECT2, also named ChM-II), initially identified as a chemokine mediating neutrophil migration, is a multifunctional secreted factor involved in diverse physiological and pathological processes. The high sequence similarity of LECT2 among different vertebrates makes it possible to explore its functions by using comparative biology. LECT2 is associated with many immune processes and immune-related diseases via its binding to cell surface receptors such as CD209a, Tie1, and Met in various cell types. In addition, the misfolding LECT2 leads to the amyloidosis of several crucial tissues (kidney, liver, and lung, etc.) by inducing the formation of insoluble fibrils. However, the mechanisms of LECT2-mediated diverse immune pathogenic conditions in various tissues remain to be fully elucidated due to the functional and signaling heterogeneity. Here, we provide a comprehensive summary of the structure, the “double-edged sword” function, and the extensive signaling pathways of LECT2 in immune diseases, as well as the potential applications of LECT2 in therapeutic interventions in preclinical or clinical trials. This review provides an integrated perspective on the current understanding of how LECT2 is associated with immune diseases, with the aim of facilitating the development of drugs or probes against LECT2 for the theranostics of immune-related diseases. |
format | Online Article Text |
id | pubmed-10034042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100340422023-03-24 The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential Zhu, Ming-Hui Liu, Yan-Jun Li, Chang-Yun Tao, Fan Yang, Guan-Jun Chen, Jiong Front Immunol Immunology Leukocyte cell-derived chemotaxin-2 (LECT2, also named ChM-II), initially identified as a chemokine mediating neutrophil migration, is a multifunctional secreted factor involved in diverse physiological and pathological processes. The high sequence similarity of LECT2 among different vertebrates makes it possible to explore its functions by using comparative biology. LECT2 is associated with many immune processes and immune-related diseases via its binding to cell surface receptors such as CD209a, Tie1, and Met in various cell types. In addition, the misfolding LECT2 leads to the amyloidosis of several crucial tissues (kidney, liver, and lung, etc.) by inducing the formation of insoluble fibrils. However, the mechanisms of LECT2-mediated diverse immune pathogenic conditions in various tissues remain to be fully elucidated due to the functional and signaling heterogeneity. Here, we provide a comprehensive summary of the structure, the “double-edged sword” function, and the extensive signaling pathways of LECT2 in immune diseases, as well as the potential applications of LECT2 in therapeutic interventions in preclinical or clinical trials. This review provides an integrated perspective on the current understanding of how LECT2 is associated with immune diseases, with the aim of facilitating the development of drugs or probes against LECT2 for the theranostics of immune-related diseases. Frontiers Media S.A. 2023-03-09 /pmc/articles/PMC10034042/ /pubmed/36969200 http://dx.doi.org/10.3389/fimmu.2023.1158083 Text en Copyright © 2023 Zhu, Liu, Li, Tao, Yang and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhu, Ming-Hui Liu, Yan-Jun Li, Chang-Yun Tao, Fan Yang, Guan-Jun Chen, Jiong The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential |
title | The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential |
title_full | The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential |
title_fullStr | The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential |
title_full_unstemmed | The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential |
title_short | The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential |
title_sort | emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: from mechanisms to therapeutic potential |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034042/ https://www.ncbi.nlm.nih.gov/pubmed/36969200 http://dx.doi.org/10.3389/fimmu.2023.1158083 |
work_keys_str_mv | AT zhuminghui theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT liuyanjun theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT lichangyun theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT taofan theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT yangguanjun theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT chenjiong theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT zhuminghui emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT liuyanjun emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT lichangyun emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT taofan emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT yangguanjun emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential AT chenjiong emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential |